Keywords: ASCO, AstraZeneca, Vandetanib, Thyroid cancer, Pfizer, Crizotinib, NSCLC, Lung cancer

AstraZeneca’s thyroid cancer drug candidate vandetanib meets Ph III goals, ASCO meeting told; Pfizer/crizotinib trial correction

Article | 08 June 2010

Print This

Presenting at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Anglo-Swedish drug major AstraZeneca said that its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in